During the medication of pazopanib, it is important to focus on preventing four risks: liver toxicity, hypertension, QT interval prolongation, and bleeding. Patients should actively cooperate with monitoring, timely identify danger signals, and ensure medication safety.

1、 Hepatotoxicity

1. Monitoring frequency

Baseline liver function must be tested before medication. After the start of treatment, it is recommended to have transaminase and bilirubin rechecks once a week for the first 4 months, and then it can be extended to once every 4 weeks or as directed by the doctor.

2. Indications for discontinuation of medication

If the transaminase significantly increases to more than three times the normal upper limit, or is accompanied by an increase in bilirubin, medication should be immediately suspended and medical attention should be sought. Do not continue taking medication.

3. Taboos

Individuals with severe liver function damage are prohibited from using it.

2、 Hypertension

1. Routine monitoring

During the medication period, blood pressure should be measured at least once a week and the values recorded.

Blood pressure should be controlled within the ideal range (usually<140/90mmHg) before treatment.

2. Handling principles

If blood pressure rises, it is necessary to start or adjust antihypertensive drugs under the guidance of a doctor. If severe hypertension (such as systolic blood pressure>200mmHg) or hypertensive crisis occurs, medication should be stopped immediately and emergency treatment should be sought.

3、 QT interval prolongation

1. High risk population

Individuals with a history of QT interval prolongation, currently taking other medications that can prolong the QT interval, or experiencing electrolyte imbalances (such as low potassium and low magnesium) have an increased risk.

2. Response measures

Electrocardiogram and electrolytes should be monitored before medication and during treatment. Avoid co administration with potent CYP3A4 inhibitors to prevent increased cardiac toxicity.

4、 Risk of bleeding

1. Bleeding identification

Pay attention to abnormal bleeding signs such as skin bruising, gum bleeding, black stool, or hematuria.

Individuals with recent active bleeding, gastrointestinal ulcers, or coagulation dysfunction should use with caution or avoid use.

2. Medication recommendations

If severe bleeding occurs, the medication should be stopped immediately and medical attention sought. Avoid using anticoagulant or antiplatelet drugs simultaneously unless deemed necessary by a doctor after evaluation.